168 related articles for article (PubMed ID: 36626436)
1. Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin.
Liang X; Liu Q; Yao W; Yang S
Medicine (Baltimore); 2022 Dec; 101(49):e31187. PubMed ID: 36626436
[TBL] [Abstract][Full Text] [Related]
2. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.
Deng C; Zhang N; Jiang S; Zhang H; Ma J; Zou W; Liu X; Hu C; Hou T
Sci Rep; 2022 Jul; 12(1):11978. PubMed ID: 35831424
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
4. Lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy increases the survival of patients with high-risk lymph node positive nasopharyngeal carcinoma.
Zhang S; Lin S; Hu L
J BUON; 2016; 21(1):161-7. PubMed ID: 27061544
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
6. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial.
Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ
JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
9. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.
Li Z; Li C; Yang D; Song J; Liu T; Zhou Z; Zhou L; Kang M
BMC Cancer; 2022 Jun; 22(1):616. PubMed ID: 35668431
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study.
Liu T; Sun Q; Chen J; Li B; Qin W; Wang F; Ye Z; Hu F
J Cancer; 2018; 9(20):3676-3682. PubMed ID: 30405836
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
13. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
Yang Z; Zuo Q; Liu R; Wu H; Xiong L; Jia J; Xiang Z
BMC Cancer; 2023 Nov; 23(1):1140. PubMed ID: 37996813
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.
Xu J; He X; Cheng K; Guo W; Bian X; Jiang X; Zhang L; Huang S
Head Neck; 2014 Oct; 36(10):1474-80. PubMed ID: 23996842
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
